Replies to post #413 on Stem Cell Innovations (fka SCLL)

[Risicare]

here


Stem Cell Innovations, Inc. (OTCBB: SCLL) announced today that the Company has started to validate a set of compounds that Circomed AG develops for certain cardiovascular indications. Financial details of this fee-for-service collaboration were not disclosed.

"This agreement confirms the broad applicability of our proprietary human liver cell C3A", said Stem Cell Innovations' CEO Dr. James Kelly. "Initially developed to serve in a liver assist device -confirming its human liver-like properties- the C3A cell has become the firm foundation under our in vitro technology suite to study compound effects for both safety and efficacy".

"We selected the C3A cell-line as it allows us to rapidly study human liver processes in a reproducible manner", said Barbara Staehelin, CEO of Circomed. "The C3A cell system combined with their broad liver biology expertise made SCI the partner of choice to assist in the progression of our molecules".

About Stem Cell Innovations, Inc.

SCI is a cell biology company with an office in Scotch Plains, N.J., and facilities in Houston, TX and in Leiden, the Netherlands. Stem Cell Innovations proprietary, human pluripotent stem cells, known as PluriCells, have the potential to aid in drug discovery, toxicology, and cell therapy. Stem Cell Innovations is in the process of making its patented pluripotent cell lines, which are eligible for federal funding in the U.S., widely available to universities and other not-for-profit institutions to rapidly advance stem cell research.

Stem Cell Innovations is positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical, and nutraceutical industries around the world. The development of the proprietary PluriCell technology greatly expands the Company's currently marketed C3A human liver cell-based toxicology offerings.